Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 1.00 |
| ▸ | PNMT | P11086 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771844 | 1.00 | CD44 (1.00) | CD44PNMTMAOBPARP1PRCP | |
| Hydrochloric Acid SCHEMBL4506036 | 0.98 | CD44 (0.96) | CD44PNMTMAOBPARP1PRCP | |
| Hydrochloric Acid SCHEMBL4520528 | 0.98 | CD44 (0.96) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL509247 | 0.86 | CD44 (0.75) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL3659651 | 0.84 | CD44 (0.72) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL30156803 | 0.84 | CD44 (0.72) | CD44PNMTMAOBPRCPHTR2C | |
| Hydrochloric Acid SCHEMBL4516826 | 0.82 | CD44 (0.70) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL329619 | 0.81 | CD44 (0.68) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL29805405 | 0.81 | CD44 (0.68) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL11327051 | 0.77 | CD44 (0.62) | CD44PNMTMAOBPARP1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024049929-A2 | PANNEXIN-1 MODULATORS AND METHODS OF TREATING DISORDERS IN WHICH PANNEXIN-1 IS IMPLICATED | PANNEX THERAPEUTICS INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2023185811-A1 | NOVEL HETEROCYCLIC COMPOUND | 首药控股(北京)股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0266949-B1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-11-28 | — | — | EP | disclosed |
| US-4812573-A | ARYLSULFONAMIDE SUBSTITUTED TETRAHYDROISOQUINOLINYLALKANOIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITHKLINE & FRENCH LABORATORIES, LTD. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0266949-A1 | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane A2 antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988003137-A1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | CD44 3096/4885PNMT 3100/4885MAOB 593/4885 |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | CD44 4875/4885PNMT 2410/4885MAOB 1087/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | CD44 4875/4885PNMT 2410/4885MAOB 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.